Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Nuclear Medicine

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 389 articles:
HTML format



Single Articles


    September 2022
  1. DERLIN T, Spencer BA, Mamach M, Abdelhafez Y, et al
    Exploring Vessel Wall Biology In Vivo By Ultra-Sensitive Total-Body Positron Emission Tomography.
    J Nucl Med. 2022 Sep 29. pii: jnumed.122.264550. doi: 10.2967/jnumed.122.264550.
    PubMed     Abstract available


  2. SEIBYL JP, DuBois JM, Racine A, Collins J, et al
    A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18-F MK-6240 Positron Emission Tomography.
    J Nucl Med. 2022 Sep 29. pii: jnumed.122.264371. doi: 10.2967/jnumed.122.264371.
    PubMed     Abstract available


  3. SMITH AM, Obuchowski NA, Foster NL, Klein G, et al
    The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264031. doi: 10.2967/jnumed.122.264031.
    PubMed     Abstract available


  4. SHANBHAG AD, Miller RJH, Pieszko K, Lemley M, et al
    Deep Learning-based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264429. doi: 10.2967/jnumed.122.264429.
    PubMed     Abstract available


  5. MORAWITZ J, Sigl B, Rubbert C, Bruckmann NM, et al
    Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on (18)F-FDG PET/MRI and machine-learning.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264138. doi: 10.2967/jnumed.122.264138.
    PubMed     Abstract available


  6. PUUVUORI E, Chiodaroli E, Estrada S, Cheung P, et al
    PET imaging of neutrophil elastase with (11)C-GW457427 in Acute Respiratory Distress Syndrome in pigs.
    J Nucl Med. 2022 Sep 15. pii: jnumed.122.264306. doi: 10.2967/jnumed.122.264306.
    PubMed     Abstract available


  7. TRAUTWEIN NF, Reischl G, Seitz C, Dittmann H, et al
    First in human PET/MRI imaging of in vivo GD2 expression in osteosarcoma.
    J Nucl Med. 2022 Sep 15. pii: jnumed.122.264626. doi: 10.2967/jnumed.122.264626.
    PubMed    


  8. BAILLY M, Thibault F, Metrard G, Courtehoux M, et al
    Precision of Myocardial Blood Flow and Flow Reserve measurement during CZT-SPECT perfusion imaging processing: intra- and inter-observer variability.
    J Nucl Med. 2022 Sep 15. pii: jnumed.122.264454. doi: 10.2967/jnumed.122.264454.
    PubMed     Abstract available


    August 2022
  9. LAFOREST R, Ghai A, Fraum TJ, Oyama R, et al
    First-in-Human Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging.
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264349. doi: 10.2967/jnumed.122.264349.
    PubMed     Abstract available


  10. PATHMANANDAVEL S, Crumbaker M, Ho B, Yam AO, et al
    Evaluation of (177)Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264398. doi: 10.2967/jnumed.122.264398.
    PubMed     Abstract available


  11. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
    Differential effects of tau stage, Lewy body pathology, and substantia nigra degeneration on FDG-PET patterns in clinical AD.
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264213. doi: 10.2967/jnumed.122.264213.
    PubMed     Abstract available


  12. HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
    Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
    J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
    PubMed     Abstract available


  13. SHIN J, Parker MFL, Zhu I, Alanizi A, et al
    Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
    PubMed     Abstract available


  14. CARLSEN EA, Loft M, Loft A, Czyzewska D, et al
    Prospective phase II trial of [(68)Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT imaging of integrin alphavbeta3 for prognostication in patients with neuroendocrine neoplasms.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264383. doi: 10.2967/jnumed.122.264383.
    PubMed     Abstract available


  15. KERSTING D, Jentzen W, Jeronim D, Mavroeidi IA, et al
    Lesion Quantification Accuracy of Digital (90)Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264338. doi: 10.2967/jnumed.122.264338.
    PubMed     Abstract available


  16. EVANGELOU P, Omrane MA, Thurow J, Mix M, et al
    (68)Ga-DOTA Positron Emission Tomography for Diagnosis of Spinal Cerebrospinal Fluid Leaks.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264059. doi: 10.2967/jnumed.122.264059.
    PubMed     Abstract available



  17. Cherry Receives 2022 Benedict Cassen Prize.
    J Nucl Med. 2022;63:10N.
    PubMed    


  18. KMETYUK Y, Czernin J, Herrmann K
    Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken Herrmann.
    J Nucl Med. 2022;63:1127-1130.
    PubMed    



  19. Schwaiger Recognized with de Hevesy Nuclear Pioneer Award.
    J Nucl Med. 2022;63:12N.
    PubMed    



  20. Mach Honored with SNMMI 2022 Paul C. Aebersold Award.
    J Nucl Med. 2022;63:13N.
    PubMed    



  21. JNM Impact Factor Rises Again.
    J Nucl Med. 2022;63:18N.
    PubMed    



  22. Science at the SNMMI Annual Meeting.
    J Nucl Med. 2022;63:19N-20N.
    PubMed    



  23. SNMMI Newsline.
    J Nucl Med. 2022;63:9N-20N.
    PubMed    


  24. PAPPAS V
    SNMMI Leadership Update: SNMMI 2022 Annual Meeting-In Person at Last.
    J Nucl Med. 2022;63:15N.
    PubMed    


  25. GONZALEZ-MONTORO A, Ullah MN, Levin CS
    Advances in Detector Instrumentation for PET.
    J Nucl Med. 2022;63:1138-1144.
    PubMed     Abstract available


  26. LEE JH, Simeon FG, Liow JS, Morse CL, et al
    In Vivo Evaluation of 6 Analogs of (11)C-ER176 as Candidate (18)F-Labeled Radioligands for 18-kDa Translocator Protein.
    J Nucl Med. 2022;63:1252-1258.
    PubMed     Abstract available


  27. BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
    Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
    J Nucl Med. 2022;63:1259-1265.
    PubMed     Abstract available


    July 2022
  28. LANG M, Spektor AM, Hielscher T, Hoppner J, et al
    Static and dynamic (68)Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas.
    J Nucl Med. 2022 Jul 29. pii: jnumed.122.264361. doi: 10.2967/jnumed.122.264361.
    PubMed     Abstract available


  29. GUEDJ E, Horowitz T
    Brain Metabolic PET Findings on the Long-Term Effects of COVID-19.
    J Nucl Med. 2022 Jul 29. pii: jnumed.122.264179. doi: 10.2967/jnumed.122.264179.
    PubMed    


  30. RUDDY TD, Al-Mallah M, Arrighi JA, Bois JP, et al
    SNMMI/ACR/ASNC/SCMR Joint Credentialing Statement for Cardiac PET/MRI.
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.264200. doi: 10.2967/jnumed.122.264200.
    PubMed    


  31. SEIBYL JP
    Alpha-synuclein PET and Parkinson's Disease Therapeutic Trials: Ever the Twain Shall Meet?
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.263918. doi: 10.2967/jnumed.122.263918.
    PubMed     Abstract available


  32. GEORGI TW, Stoevesandt D, Kurch L, Bartelt JM, et al
    Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.264112. doi: 10.2967/jnumed.122.264112.
    PubMed     Abstract available


  33. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
    Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
    PubMed     Abstract available


  34. KIM MJ, Juarez Anaya F, Manly LS, Lee JH, et al
    Whole-body PET imaging in humans shows that (11)C-PS13 is selective for cyclooxygenase-1 and can measure the in vivo potency of nonsteroidal anti-inflammatory drugs.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264061. doi: 10.2967/jnumed.122.264061.
    PubMed     Abstract available


  35. ISHII K, Hanaoka K, Watanabe S, Morimoto-Ishikawa D, et al
    High-resolution silicon photomultiplier time-of-flight dedicated head PET system for clinical brain studies.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264080. doi: 10.2967/jnumed.122.264080.
    PubMed     Abstract available


  36. LI RG, Stenberg VY, Larsen RH
    A Novel Experimental Generator for Production of High Purity Lead-212 for Use in Radiopharmaceuticals.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264009. doi: 10.2967/jnumed.122.264009.
    PubMed     Abstract available



  37. SNMMI Image of the Year 2022: PET/CT Biomarker Predicts Post-MI Cardiac Remodeling.
    J Nucl Med. 2022;63:16N.
    PubMed    


  38. STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
    Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.
    J Nucl Med. 2022;63:986-994.
    PubMed     Abstract available



  39. New Officers for SNMMI and SNMMI-TS.
    J Nucl Med. 2022;63:17N-18N.
    PubMed    


  40. CZERNIN J, Adams T, Calais J
    More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging.
    J Nucl Med. 2022;63:969-970.
    PubMed    


  41. GHESANI M
    SNMMI Leadership Update: Opportunities for Growth in Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2022;63:20N.
    PubMed    


  42. SEGALL G
    Recognition of the ABNM by the NRC.
    J Nucl Med. 2022;63:19N.
    PubMed    



  43. SNMMI Newsline.
    J Nucl Med. 2022;63:15N-26N.
    PubMed    


  44. GRKOVSKI M, Modak S, Zanzonico PB, Carrasquillo JA, et al
    Biodistribution and Radiation Dosimetry of Intraperitoneally Administered (124)I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.
    J Nucl Med. 2022;63:1094-1100.
    PubMed     Abstract available


  45. DRESSING A, Bormann T, Blazhenets G, Schroeter N, et al
    Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome.
    J Nucl Med. 2022;63:1058-1063.
    PubMed     Abstract available


    June 2022
  46. PARIHAR AS, Mhlanga J, Ronstrom C, Schmidt LR, et al
    Diagnostic accuracy of (99m)Tc-Sestamibi SPECT/CT for characterization of solid renal masses.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264329. doi: 10.2967/jnumed.122.264329.
    PubMed     Abstract available


  47. SHIYAM SUNDAR LK, Yu J, Muzik O, Kulterer O, et al
    Fully-automated, semantic segmentation of whole-body (18)F-FDG PET/CT images based on data-centric artificial intelligence.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264063. doi: 10.2967/jnumed.122.264063.
    PubMed     Abstract available


  48. WAKABAYASHI Y, Strenkona P, Arakawa R, Yan X, et al
    First-in-human evaluation of (18)F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.263838. doi: 10.2967/jnumed.122.263838.
    PubMed     Abstract available


  49. ZHOU R, Choi H, Cao J, Pantel A, et al
    (18)F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264152. doi: 10.2967/jnumed.122.264152.
    PubMed     Abstract available


  50. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
    The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
    PubMed     Abstract available


  51. LE TM, Lee HR, Abt ER, Rashid K, et al
    (18)F-FDG PET visualizes systemic STING agonist-induced lymphocyte activation in preclinical models.
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264121. doi: 10.2967/jnumed.122.264121.
    PubMed     Abstract available


  52. ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
    (89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
    J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
    PubMed     Abstract available


  53. REICHKENDLER M, Andersen FL, Borgwardt L, Nygaard U, et al
    Long axial field of view with 5 min acquisition time enables PET/CT in toddler without sedation.
    J Nucl Med. 2022 Jun 16. pii: jnumed.121.263626. doi: 10.2967/jnumed.121.263626.
    PubMed    


  54. NITSCHE C, Mascherbauer K, Calabretta R, Koschutnik M, et al
    Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy.
    J Nucl Med. 2022 Jun 16. pii: jnumed.122.264041. doi: 10.2967/jnumed.122.264041.
    PubMed     Abstract available


  55. GIRUM KB, Rebaud L, Cottereau AS, Meignan M, et al
    (18)F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients.
    J Nucl Med. 2022 Jun 16. pii: jnumed.121.263501. doi: 10.2967/jnumed.121.263501.
    PubMed     Abstract available


  56. ANTONI G, Lubberink M, Sorensen J, Lindstrom E, et al
    In Vivo Visualization and Quantification of Neutrophil Elastase in Lungs of COVID-19 Patients - A First-In-Human Positron Emission Tomography Study with (11)C-GW457427.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.263974. doi: 10.2967/jnumed.122.263974.
    PubMed     Abstract available


  57. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    PubMed     Abstract available


  58. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    PubMed    


  59. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    


  60. MINOSHIMA S, Cross D, Thientunyakit T, Foster NL, et al
    (18)F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  61. CHAPLEAU M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD, et al
    The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  62. TIEPOLT S, Meyer PM, Patt M, Deuther-Conrad W, et al
    PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  63. GROOT C, Villeneuve S, Smith R, Hansson O, et al
    Tau PET Imaging in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  64. KENOU BV, Manly LS, Rubovits SB, Umeozulu SA, et al
    Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia.
    J Nucl Med. 2022;63.
    PubMed     Abstract available



  65. SNMMI Newsline.
    J Nucl Med. 2022;63:13N-35N.
    PubMed    



  66. Outstanding JNMT Articles for 2021.
    J Nucl Med. 2022;63:13N.
    PubMed    


  67. WAHL RL
    SNMMI Leadership Update: Putting Patients First: A Year in Review.
    J Nucl Med. 2022;63:14N.
    PubMed    


  68. CARSON RE, Naganawa M, Toyonaga T, Koohsari S, et al
    Imaging of Synaptic Density in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  69. MASDEU JC, Pascual B, Fujita M
    Imaging Neuroinflammation in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  70. BARTHEL H, Villemagne VL, Drzezga A
    Future Directions in Molecular Imaging of Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  71. VILLEMAGNE VL, Barthel H
    Molecular Imaging of Neurodegeneration: The Way to New Horizons.
    J Nucl Med. 2022;63.
    PubMed    


  72. LEE ST, Emmett LM, Pattison DA, Hofman MS, et al
    The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.
    J Nucl Med. 2022;63:819-822.
    PubMed     Abstract available


  73. WU M, Ning J, Li J, Lai Z, et al
    Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls.
    J Nucl Med. 2022;63:948-951.
    PubMed     Abstract available


  74. BERTOGLIO D, Verhaeghe J, Wyffels L, Miranda A, et al
    Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    J Nucl Med. 2022;63:942-947.
    PubMed     Abstract available


  75. COUSINS MM, Devasia TP, Maurino CM, Mikell J, et al
    Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After (90)Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.
    J Nucl Med. 2022;63:882-889.
    PubMed     Abstract available


    May 2022
  76. GLATTING FM, Hoppner J, Liew DP, van Genabith A, et al
    Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264069. doi: 10.2967/jnumed.122.264069.
    PubMed     Abstract available


  77. SARTOR O
    Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
    PubMed    


  78. JHA AK, Bradshaw TJ, Buvat I, Hatt M, et al
    Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE guidelines).
    J Nucl Med. 2022 May 26. pii: jnumed.121.263239. doi: 10.2967/jnumed.121.263239.
    PubMed     Abstract available


  79. OUVRARD E, De Mestier L, Boursier C, Lachachi B, et al
    (18)F-Fluorodihydroxyphenylalanine PET/CT at the Forefront for Initial and/or Pre-surgical Evaluation of Small Intestine Neuroendocrine Tumors.
    J Nucl Med. 2022 May 19. pii: jnumed.122.263984. doi: 10.2967/jnumed.122.263984.
    PubMed     Abstract available


  80. LOFT M, Christensen C, Clausen MM, Carlsen EA, et al
    First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using (18)F-labeled Active-Site Inhibited Factor VII ((18)F-ASIS): Potential as Companion Diagnostic.
    J Nucl Med. 2022 May 19. pii: jnumed.122.264068. doi: 10.2967/jnumed.122.264068.
    PubMed     Abstract available


  81. LOVINFOSSE P, Ferreira M, Withofs N, Jadoul A, et al
    Distinction of lymphoma from sarcoidosis at FDG PET/CT - evaluation of radiomic-feature guided machine learning versus human reader performance.
    J Nucl Med. 2022 May 19. pii: jnumed.121.263598. doi: 10.2967/jnumed.121.263598.
    PubMed     Abstract available


  82. ABDELHAFEZ Y, Raychaudhuri SP, Mazza D, Sarkar S, et al
    Total-Body (18)F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations.
    J Nucl Med. 2022 May 19. pii: jnumed.121.263774. doi: 10.2967/jnumed.121.263774.
    PubMed     Abstract available


  83. BARTOS LM, Kunte ST, Beumers P, Xiang X, et al
    Single cell radiotracer allocation via immunomagentic sorting (scRadiotracing) to disentangle PET signals at cellular resolution.
    J Nucl Med. 2022 May 19. pii: jnumed.122.264171. doi: 10.2967/jnumed.122.264171.
    PubMed     Abstract available


  84. SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
    (18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
    PubMed     Abstract available


  85. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
    Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
    PubMed     Abstract available


  86. ERBA PA, Natali A, Strauss HW, Mariani G, et al
    Brown Adipose Tissue Activity Following Exposure to the Cold and [(18)F]FDG Uptake: from Possible Pitfall in Early PET Scans to Metabolic Biomarker.
    J Nucl Med. 2022 May 12. pii: jnumed.122.264188. doi: 10.2967/jnumed.122.264188.
    PubMed    


  87. VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
    (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
    J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
    PubMed     Abstract available


  88. MORADI F, Duan H, Song H, Davidzon GA, et al
    (68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
    J Nucl Med. 2022 May 5. pii: jnumed.122.263897. doi: 10.2967/jnumed.122.263897.
    PubMed     Abstract available


  89. HOPE TA, Jadvar H
    Updates to Appropriate Use Criteria for PSMA PET.
    J Nucl Med. 2022;63:14N.
    PubMed    


  90. WAHL RL
    SNMMI Leadership Update: SNMMI's Role in the Nuclear Medicine Renaissance.
    J Nucl Med. 2022;63:16N-17N.
    PubMed    



  91. SNMMI Newsline.
    J Nucl Med. 2022;63:13N-24N.
    PubMed    



  92. ASNC/SNMMI Radionuclide Authorized User Training Course.
    J Nucl Med. 2022;63:15N.
    PubMed    


  93. STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
    Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging.
    J Nucl Med. 2022;63:649-658.
    PubMed     Abstract available


  94. SALAS JR, Clark PM
    Signaling Pathways That Drive (18)F-FDG Accumulation in Cancer.
    J Nucl Med. 2022;63:659-663.
    PubMed     Abstract available


  95. TAMBORINO G, Perrot Y, De Saint-Hubert M, Struelens L, et al
    Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy.
    J Nucl Med. 2022;63:761-769.
    PubMed     Abstract available


  96. ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
    Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.
    J Nucl Med. 2022;63:794-800.
    PubMed     Abstract available


  97. HANSCHEID H, Schirbel A, Hartrampf P, Kraus S, et al
    Biokinetics and Dosimetry of (177)Lu-Pentixather.
    J Nucl Med. 2022;63:754-760.
    PubMed     Abstract available


  98. FERDINANDUS J, Costa PF, Kessler L, Weber M, et al
    Initial Clinical Experience with (90)Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients.
    J Nucl Med. 2022;63:727-734.
    PubMed     Abstract available


    April 2022
  99. BROOKS AL, Winton W, Stauff J, Arteaga J, et al
    Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET.
    J Nucl Med. 2022 Apr 28. pii: jnumed.122.263864. doi: 10.2967/jnumed.122.263864.
    PubMed     Abstract available


  100. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
    Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
    PubMed     Abstract available


  101. CHERK MH, Khor R, Barber TW, Yap KSK, et al
    Non-Invasive Assessment of Acute Graft vs. Host Disease of the Gastrointestinal Tract Following Allogeneic Haemopoietic Stem Cell Transplantation Using (18)F-FDG PET.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263688. doi: 10.2967/jnumed.121.263688.
    PubMed     Abstract available


  102. PIRASTEH A, Periyasamy S, Meudt JJ, Lui Y, et al
    Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor Positron Emission Tomography in a Human-sized Swine Model.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263736. doi: 10.2967/jnumed.121.263736.
    PubMed     Abstract available


  103. BROER LN, Knapen DG, Suurs FV, Moen I, et al
    (89)Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted (227)Th-conjugate therapy in mice.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263079. doi: 10.2967/jnumed.121.263079.
    PubMed     Abstract available


  104. ROTH KS, Voltin CA, van-Heek L, Wegen S, et al
    Dual-tracer PET/CT protocol with [(18)F]-FDG and [(68)Ga]Ga-FAPI-46 for cancer imaging - a proof of concept.
    J Nucl Med. 2022 Apr 14. pii: jnumed.122.263835. doi: 10.2967/jnumed.122.263835.
    PubMed     Abstract available


  105. DEWARAJA YK, Mirando DM, Peterson A, Niedbala J, et al
    A pipeline for automated voxel dosimetry: application in patients with multi-SPECT/CT imaging following (177)Lu peptide receptor radionuclide therapy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263738. doi: 10.2967/jnumed.121.263738.
    PubMed     Abstract available


  106. MESSERSCHMIDT K, Barthel H, Brendel M, Scherlach C, et al
    (18)F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.262854. doi: 10.2967/jnumed.121.262854.
    PubMed     Abstract available


  107. ROSEN J, Ceccon G, Bauer EK, Werner JM, et al
    Cost-effectiveness of (18)F-FET PET for early treatment response assessment in glioma patients following adjuvant temozolomide chemotherapy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.122.263790. doi: 10.2967/jnumed.122.263790.
    PubMed     Abstract available


  108. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
    Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
    PubMed     Abstract available


  109. KUWERT T, Schmidkonz C, Prante O, Schett G, et al
    FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases.
    J Nucl Med. 2022 Apr 7. pii: jnumed.122.263922. doi: 10.2967/jnumed.122.263922.
    PubMed     Abstract available


  110. KROENKE M, Schweiger L, Horn T, Haller B, et al
    Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
    PubMed     Abstract available


  111. GORDON L
    ABNM: Nuclear Medicine In-Training Examination Goes Virtual.
    J Nucl Med. 2022;63:18N.
    PubMed    



  112. SNMMI Calls for Expanded Coverage/Reimbursement of Amyloid PET.
    J Nucl Med. 2022;63:17N.
    PubMed    


  113. PAPPAS V
    SNMMI Leadership Update: SNMMI Meetings Back in Full Swing.
    J Nucl Med. 2022;63:19N.
    PubMed    



  114. SNMMI Newsline.
    J Nucl Med. 2022;63:15N-26N.
    PubMed    


  115. NELSON BJB, Ferguson S, Wuest M, Wilson J, et al
    First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La.
    J Nucl Med. 2022;63:584-590.
    PubMed     Abstract available


    March 2022
  116. EMMETT LM, Papa N, Buteau J, Ho B, et al
    The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
    PubMed     Abstract available


  117. LEE J, Burkett BJ, Min HK, Lundt ES, et al
    The Overlap Index as a means of evaluating early tau-PET signal reliability.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263136. doi: 10.2967/jnumed.121.263136.
    PubMed     Abstract available


  118. ZARAGORI T, Verger A
    Reply to Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study".
    J Nucl Med. 2022 Mar 17. pii: jnumed.122.264035. doi: 10.2967/jnumed.122.264035.
    PubMed    


  119. HOTTA M, Gafita A, Czernin J, Calais J, et al
    Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
    PubMed     Abstract available


  120. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
    (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
    PubMed     Abstract available


  121. SUILAMO S, Li XG, Lankinen P, Oikonen V, et al
    (68)Ga-Citrate Positron Emission Tomography of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates.
    J Nucl Med. 2022 Mar 10. pii: jnumed.122.263884. doi: 10.2967/jnumed.122.263884.
    PubMed     Abstract available


  122. FONTI R, Panico M, Pellegrino S, Pulcrano A, et al
    Heterogeneity of SSTR2 expression assessed by (68)Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262928. doi: 10.2967/jnumed.121.262928.
    PubMed     Abstract available


  123. PANTEL AR, Mankoff DA, Karp JS
    Total Body PET - Will it Change Science and Practice?
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263481. doi: 10.2967/jnumed.121.263481.
    PubMed    


  124. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
    PubMed     Abstract available


  125. BUCK AK, Haug A, Dreher N, Lambertini A, et al
    Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263693. doi: 10.2967/jnumed.121.263693.
    PubMed     Abstract available



  126. SNMMI Launches Radiopharmaceutical Therapy Centers of Excellence Program.
    J Nucl Med. 2022;63:14N.
    PubMed    


  127. PRASAD V, Boss M, Rottenburger C, Brenner W, et al
    Reply: (68)Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
    J Nucl Med. 2022;63:493-494.
    PubMed    


  128. BANERJEE I, Sajjan R, Estebanez MS, Dunne MJ, et al
    (68)Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
    J Nucl Med. 2022;63:493.
    PubMed    


  129. GULUDEC DL, Czernin J, Calais J
    Health Care and Nuclear Medicine in France: A Conversation Between Dominique Le Guludec, Johannes Czernin, and Jeremie Calais.
    J Nucl Med. 2022;63:327-330.
    PubMed    


  130. TZOLOS E, Kwiecinski J, Berman D, Slomka P, et al
    Latest Advances in Multimodality Imaging of Aortic Stenosis.
    J Nucl Med. 2022;63:353-358.
    PubMed     Abstract available


  131. SARI H, Reaungamornrat J, Catalano OA, Vera-Olmos J, et al
    Evaluation of Deep Learning-Based Approaches to Segment Bowel Air Pockets and Generate Pelvic Attenuation Maps from CAIPIRINHA-Accelerated Dixon MR Images.
    J Nucl Med. 2022;63:468-475.
    PubMed     Abstract available


  132. DING J, Tong A, Zhang Y, Wen J, et al
    Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor.
    J Nucl Med. 2022;63:368-375.
    PubMed     Abstract available


  133. ROTH D, Gustafsson J, Warfvinge CF, Sundlov A, et al
    Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with (177)Lu-DOTATATE.
    J Nucl Med. 2022;63:399-405.
    PubMed     Abstract available


  134. EERTINK JJ, Pfaehler EAG, Wiegers SE, van T, et al
    Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
    J Nucl Med. 2022;63:389-395.
    PubMed     Abstract available


  135. LASSEN ML, Byrne C, Sheykhzade M, Wissenberg M, et al
    Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia.
    J Nucl Med. 2022;63:431-437.
    PubMed     Abstract available


  136. VIRGOLINI I, Bahri S, Kjaer A, Gronbaek H, et al
    A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    J Nucl Med. 2022;63:376-383.
    PubMed     Abstract available


  137. BAUM RP, Schuchardt C, Singh A, Chantadisai M, et al
    Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results.
    J Nucl Med. 2022;63:415-423.
    PubMed     Abstract available


  138. WAHL RL
    SNMMI Leadership Update: Call the Nuclear Oncologist.
    J Nucl Med. 2022;63:15N.
    PubMed    



  139. SNMMI Statement: Possible Effect of Omicron Infection on (18)F-FDG-Based Imaging.
    J Nucl Med. 2022;63:11N.
    PubMed    



  140. SNMMI Newsline.
    J Nucl Med. 2022;63:11N-22N.
    PubMed    


    February 2022
  141. LEITHNER D, Schoder H, Haug AR, Vargas HA, et al
    Impact of ComBat harmonization on PET radiomics-based tissue classification: a dual-center PET/MR and PET/CT study.
    J Nucl Med. 2022 Feb 24. pii: jnumed.121.263102. doi: 10.2967/jnumed.121.263102.
    PubMed     Abstract available


  142. YANG Z, Li F, Huang Y, Yin N, et al
    Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma.
    J Nucl Med. 2022 Feb 24. pii: jnumed.121.263151. doi: 10.2967/jnumed.121.263151.
    PubMed     Abstract available


  143. LUCOT KL, Stevens MY, Bonham TA, Azevedo EC, et al
    TRACKING INNATE IMMUNE ACTIVATION IN A MOUSE MODEL OF PARKINSON'S DISEASE USING TREM1 AND TSPO PET TRACERS.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263039. doi: 10.2967/jnumed.121.263039.
    PubMed     Abstract available


  144. WU WY, Yu F, Zhang PJ, Bu T, et al
    (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
    PubMed     Abstract available


  145. FORAY C, Barca C, Winkeler A, Wagner S, et al
    Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263318. doi: 10.2967/jnumed.121.263318.
    PubMed     Abstract available


  146. BARCA C, Kiliaan AJ, Wachsmuth L, Foray C, et al
    Short-term colony stimulating factor-1 receptor inhibition-induced repopulation after stroke assessed by longitudinal (18)F-DPA-714 PET imaging.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263004. doi: 10.2967/jnumed.121.263004.
    PubMed     Abstract available


  147. ZHANG X, Li M, Gai Y, Chen J, et al
    (18)F-PFPN PET: a new and attractive imaging modality for patients with malignant melanoma.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263179. doi: 10.2967/jnumed.121.263179.
    PubMed     Abstract available


  148. ZANOTTI-FREGONARA P, Ishiguro T, Yoshihara K, Ishii S, et al
    (18)F-FDG Fetal Dosimetry Calculated with PET/MRI.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263561. doi: 10.2967/jnumed.121.263561.
    PubMed     Abstract available



  149. FDA Approves New (68)Ga Kit for Prostate Cancer PET.
    J Nucl Med. 2022;63:26N.
    PubMed    


  150. WAHL RL
    SNMMI to Host Summits on Artificial Intelligence and Patient Access.
    J Nucl Med. 2022;63:27N.
    PubMed    


  151. ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
    Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
    J Nucl Med. 2022;63:218-225.
    PubMed     Abstract available


  152. GILLESSEN S, Czernin J, Herrmann K
    A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann.
    J Nucl Med. 2022;63:169-171.
    PubMed    


  153. ORLHAC F, Eertink JJ, Cottereau AS, Zijlstra JM, et al
    A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies.
    J Nucl Med. 2022;63:172-179.
    PubMed     Abstract available


  154. KHODAII J, Araj-Khodaei M, Vafaee MS, Wong DF, et al
    Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots.
    J Nucl Med. 2022;63:294-301.
    PubMed     Abstract available


  155. ZHANG Y, Kupferschlaeger J, Lang P, Reischl G, et al
    (131)I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors.
    J Nucl Med. 2022;63:205-211.
    PubMed     Abstract available


    January 2022
  156. VILEMAGNE VL, Harada R, Dore V, Furumoto S, et al
    First-in-human evaluation of (18)F-SMBT-1, a novel (18)F-labeled MAO-B PET tracer for imaging reactive astrogliosis.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263254. doi: 10.2967/jnumed.121.263254.
    PubMed     Abstract available


  157. ALBERGE JB, Kraeber-Bodere F, Jamet B, Touzeau C, et al
    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.262884. doi: 10.2967/jnumed.121.262884.
    PubMed     Abstract available


  158. SPANGLER-BICKELL MG, Hurley SA, Pirasteh A, Perlman SB, et al
    Evaluation of Data-Driven Rigid Motion Correction in Clinical Brain PET Imaging.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263309. doi: 10.2967/jnumed.121.263309.
    PubMed     Abstract available


  159. KUO PH, Benson T, Messmann R, Groaning M, et al
    Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263638. doi: 10.2967/jnumed.121.263638.
    PubMed    


  160. SEO M, Kim Y, Ye BD, Park SH, et al
    Positron emission tomography imaging of system xc(-) in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263289. doi: 10.2967/jnumed.121.263289.
    PubMed     Abstract available


  161. LANGEN KJ, Mottaghy FM
    Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study" [J Nucl Med 2022; 63:147-157].
    J Nucl Med. 2022 Jan 27. pii: jnumed.122.263837. doi: 10.2967/jnumed.122.263837.
    PubMed    


  162. WESTDORP H, Verhoeff SR, Gotthardt M, van Herpen CML, et al
    Towards a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.262622. doi: 10.2967/jnumed.121.262622.
    PubMed    


  163. NG M, Guerrieri M, Wong LM, Taubman K, et al
    The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
    PubMed     Abstract available


  164. CARLSEN EA, Loft M, Loft A, Berthelsen AK, et al
    Prospective phase II trial of prognostication by (68)Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263177. doi: 10.2967/jnumed.121.263177.
    PubMed     Abstract available


  165. BUNNING S, Ignace C, Mattmuller S, Schwarz SW, et al
    Proceedings: PET Drugs: A Workshop on Inspections Management and Regulatory Considerations.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263443. doi: 10.2967/jnumed.121.263443.
    PubMed     Abstract available


  166. PRIVE BM, Peters S, Uijen MJM, Janssen MJR, et al
    Letter to the Editor RE: Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2022 Jan 13. pii: jnumed.122.263802. doi: 10.2967/jnumed.122.263802.
    PubMed    


  167. BERTOGLIO D, Halloin N, De Lombaerde S, Jankovski A, et al
    SV2A PET imaging is a non-invasive marker for the detection of spinal damages in experimental models of spinal cord injury.
    J Nucl Med. 2022 Jan 13. pii: jnumed.121.263222. doi: 10.2967/jnumed.121.263222.
    PubMed     Abstract available


  168. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    PubMed     Abstract available


  169. DRIESSEN J, Zwezerijnen GJ, Schoder H, Drees EE, et al
    The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263067. doi: 10.2967/jnumed.121.263067.
    PubMed     Abstract available


  170. WAHL RL
    Ensuring Quality and Safety in Nuclear Medicine Imaging and Therapy.
    J Nucl Med. 2022;63:18N.
    PubMed    


  171. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    PubMed     Abstract available


  172. HICKS R, Czernin J, Herrmann K
    Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann.
    J Nucl Med. 2022;63:1-4.
    PubMed    


    December 2021
  173. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
    Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
    J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
    PubMed     Abstract available


  174. LI E, Spencer BA, Schmall JP, Abdelhafez Y, et al
    Efficient delay correction for total-body PET kinetic modeling using pulse timing methods.
    J Nucl Med. 2021 Dec 21. pii: jnumed.121.262968. doi: 10.2967/jnumed.121.262968.
    PubMed     Abstract available


  175. CHOI YJ, Koh Y, Lee HJ, Hwang IC, et al
    Independent Prognostic Utility of (11)C-Pittsburgh Compound B Positron Emission Tomography in Light-Chain Cardiac Amyloidosis Patients.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.263033. doi: 10.2967/jnumed.121.263033.
    PubMed     Abstract available


  176. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
    Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
    PubMed     Abstract available


  177. ZEYDAN B, Schwarz CG, Przybelski SA, Lesnick TG, et al
    Comparison of (11)C-Pittsburgh compound-B and (18)F-Flutemetamol White Matter Binding in PET.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.263281. doi: 10.2967/jnumed.121.263281.
    PubMed     Abstract available


  178. LI C, Han C, Duan S, Li P, et al
    Visualizing T cell responses: The T cell PET imaging toolbox.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.261976. doi: 10.2967/jnumed.121.261976.
    PubMed     Abstract available


  179. FRIEDMAN NC
    The Will Rodgers Phenomenon and PSMA PET/CT.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.263556. doi: 10.2967/jnumed.121.263556.
    PubMed    


  180. CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
    FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
    PubMed     Abstract available


  181. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
    Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
    PubMed     Abstract available


  182. SEBAN RD, Richard C, Nascimento-Leite C, Ghidaglia J, et al
    Absolute lymphocyte count after COVID-19 vaccination is associated with vaccine-induced hypermetabolic lymph nodes on (18)F-FDG PET/CT: a focus in breast cancer care.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.263082. doi: 10.2967/jnumed.121.263082.
    PubMed     Abstract available


  183. MORTIMER JE, Bading JR, Frankel PH, Caroll M, et al
    Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262940. doi: 10.2967/jnumed.121.262940.
    PubMed     Abstract available


  184. BOUDOUSQ V, Guignard N, Gilly O, Chambert B, et al
    Diagnostic performances of cervical ultrasound, sestamibi scintigraphy and contrast-enhanced (18)F-fluorocholine positron emission tomography in primary hyperparathyroidism.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.261900. doi: 10.2967/jnumed.121.261900.
    PubMed     Abstract available


  185. RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
    Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
    PubMed     Abstract available


  186. BARRINGTON SF, Mir F, El-Galaly TC, Knapp A, et al
    Follicular lymphoma treated with first-line immunochemotherapy: a review of PET-CT in patients who did not achieve CMR in the GALLIUM study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262869. doi: 10.2967/jnumed.121.262869.
    PubMed     Abstract available


  187. PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
    Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
    PubMed     Abstract available


  188. LASSMANN M, Eberlein U, Gear J, Konijnenberg M, et al
    Dosimetry for Radiopharmaceutical Therapy: The European Perspective.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  189. PANDIT-TASKAR N, Iravani A, Lee D, Jacene H, et al
    Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  190. GRAVES SA, Bageac A, Crowley JR, Merlino DAM, et al
    Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  191. CAPALA J, Graves SA, Scott A, Sgouros G, et al
    Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  192. WAHL RL, Sgouros G, Iravani A, Jacene H, et al
    Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.
    J Nucl Med. 2021;62.
    PubMed    


  193. WAHL RL, Sunderland J
    Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice.
    J Nucl Med. 2021;62.
    PubMed    


  194. SGOUROS G, Dewaraja YK, Escorcia F, Graves SA, et al
    Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  195. URIBE C, Peterson A, Van B, Fedrigo R, et al
    An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


    November 2021
  196. COSTA GCA, Spencer BA, Omidvari N, Foster C, et al
    Radioembolization Dosimetry with Total-Body (90)Y PET.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.263145. doi: 10.2967/jnumed.121.263145.
    PubMed     Abstract available


  197. WANG G, Nardo L, Parikh M, Abdelhafez YG, et al
    Total-Body PET Multiparametric Imaging of Cancer Using a Voxel-wise Strategy of Compartmental Modeling.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262668. doi: 10.2967/jnumed.121.262668.
    PubMed     Abstract available


  198. MALPETTI M, Kaalund SS, Tsvetanov KA, Rittman T, et al
    In vivo (18)F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262985. doi: 10.2967/jnumed.121.262985.
    PubMed     Abstract available


  199. THEISEN AL, Lassmann M, Tran-Gia J
    Towards a patient-specific traceable quantification of SPECT/CT-based radiopharmaceutical distributions.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262925. doi: 10.2967/jnumed.121.262925.
    PubMed     Abstract available


  200. REDDY RP, Schmidtlein CR, Giancipoli RG, Mauguen A, et al
    The quest for an accurate functional tumor volume with (68)Ga-DOTATATE PET/CT.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.262782. doi: 10.2967/jnumed.121.262782.
    PubMed     Abstract available


  201. STELLA M, van Rooij R, Lam M, de Jong H, et al
    Lung dose measured on post-radioembolization (90)Y-PET/CT and incidence of radiation pneumonitis.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263143. doi: 10.2967/jnumed.121.263143.
    PubMed     Abstract available


  202. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    PubMed     Abstract available


  203. MONA CE, Benz MR, Hikmat F, Grogan TR, et al
    Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262426. doi: 10.2967/jnumed.121.262426.
    PubMed     Abstract available


  204. BRADSHAW TJ, Boellaard R, Dutta J, Jha AK, et al
    Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262567. doi: 10.2967/jnumed.121.262567.
    PubMed     Abstract available


  205. YOUNIS MH, Lan X, Cai W
    PET with a (68)Ga-labeled FAPI dimer: moving towards theranostics.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263292. doi: 10.2967/jnumed.121.263292.
    PubMed    


  206. THUILLIER P, Liberini V, Grimaldi S, Rampado O, et al
    Prognostic value of whole-body PET volumetric parameters extracted from (68)Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262652. doi: 10.2967/jnumed.121.262652.
    PubMed     Abstract available


  207. KESNER AL
    Commercially competitive vendor-agnostic image reconstruction could be a leap forward for PET harmonization.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263421. doi: 10.2967/jnumed.121.263421.
    PubMed    


  208. NIMMAGADDA S
    Imaging PD-L1 expression in melanoma brain metastases.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263209. doi: 10.2967/jnumed.121.263209.
    PubMed    


  209. SCOTT AM, Czernin J
    Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin.
    J Nucl Med. 2021;62:1492-1494.
    PubMed    


  210. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    PubMed    


  211. PARKER MFL, Blecha J, Rosenberg O, Ohliger M, et al
    Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2.
    J Nucl Med. 2021;62:1631-1637.
    PubMed     Abstract available


  212. HORSAGER J, Knudsen K, Borghammer P
    Radionuclide Imaging of the Gut-Brain Axis in Parkinson Disease.
    J Nucl Med. 2021;62:1504-1505.
    PubMed    


  213. MILLER RJH, Sharir T, Otaki Y, Gransar H, et al
    Quantitation of Poststress Change in Ventricular Morphology Improves Risk Stratification.
    J Nucl Med. 2021;62:1582-1590.
    PubMed     Abstract available


  214. BAUM RP, Zhang J, Schuchardt C, Muller D, et al
    First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.
    J Nucl Med. 2021;62:1571-1581.
    PubMed     Abstract available


  215. PARGHANE RV, Bhandare M, Chaudhari V, Ostwal V, et al
    Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant (177)Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors.
    J Nucl Med. 2021;62:1558-1563.
    PubMed     Abstract available


  216. ZHOU Z, Meshaw R, Zalutsky MR, Vaidyanathan G, et al
    Site-Specific and Residualizing Linker for (18)F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.
    J Nucl Med. 2021;62:1624-1630.
    PubMed     Abstract available


    October 2021
  217. YUSUFALY T, Zou J, Nelson T, Williamson C, et al
    Improved Prognosis of Treatment Failure in Cervical Cancer with Non-Tumor Positron Emission Tomography / Computed Tomography Radiomics.
    J Nucl Med. 2021 Oct 28. pii: jnumed.121.262618. doi: 10.2967/jnumed.121.262618.
    PubMed     Abstract available


  218. AHLMAN MA, Maass-Moreno R, Grayson PC peter.gray
    Reply LTE, On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessel Vasculitis.
    J Nucl Med. 2021 Oct 28. pii: jnumed.121.263158. doi: 10.2967/jnumed.121.263158.
    PubMed    


  219. BURGGRAAFF CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, et al
    (18)F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: The HOVON-84 study.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262205. doi: 10.2967/jnumed.121.262205.
    PubMed     Abstract available


  220. GHEYSENS O, Belkhir L, Jamar F
    Imaging in Post-COVID Lung Disease (PCLD): does [(18)F]-FDG-PET/CT have the Key?
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.263166. doi: 10.2967/jnumed.121.263166.
    PubMed    


  221. LASNON C, Girault G, Lebtahi R, Ansquer C, et al
    Women Authors in Nuclear Medicine Journals: a Survey from 2014 to 2020.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262773. doi: 10.2967/jnumed.121.262773.
    PubMed     Abstract available


  222. MIYAHIRA AK, Soule HR
    The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
    PubMed     Abstract available


  223. SCHMIDKONZ C
    Perspective on Fibroblast Activation Protein Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis - a New Paradigm for Molecular Imaging?
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262944. doi: 10.2967/jnumed.121.262944.
    PubMed    


  224. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    PubMed     Abstract available


  225. LE ROUX PY, Bonnefoy PB, Bahloul A, Denizot B, et al
    Lung scintigraphy for pulmonary embolism diagnosis in COVID-19 patients: a multicenter study.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262955. doi: 10.2967/jnumed.121.262955.
    PubMed     Abstract available


  226. RISCHKA L, Vraka C, Pichler V, Rasul S, et al
    First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-(11)C-Me-NB1.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262427. doi: 10.2967/jnumed.121.262427.
    PubMed     Abstract available


  227. FERDINANDUS J, Fendler WP, Farolfi A, Washington S, et al
    PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262821. doi: 10.2967/jnumed.121.262821.
    PubMed     Abstract available


  228. KESSLER L, Ferdinandus J, Hirmas N, Zarrad F, et al
    Pitfalls and common findings in (68)Ga-FAPI-PET - A pictorial analysis.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262808. doi: 10.2967/jnumed.121.262808.
    PubMed     Abstract available


  229. MAHAJAN S, Barker CA, Mauguen A, D'Angelo SP, et al
    (18)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262882. doi: 10.2967/jnumed.121.262882.
    PubMed     Abstract available


  230. BARATTO L, Hawk KE, States L, Qi J, et al
    PET/MRI Improves Management of Children with Cancer.
    J Nucl Med. 2021;62:1334-1340.
    PubMed     Abstract available


  231. JOHNSON BJ, Van Abel KM, Ma DJ, Johnson DR, et al
    (18)F-FDG-Avid Axillary Lymph Nodes After COVID-19 Vaccination.
    J Nucl Med. 2021;62:1483-1484.
    PubMed    


  232. PARK S, Parihar AS, Bodei L, Hope TA, et al
    Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
    J Nucl Med. 2021;62:1323-1329.
    PubMed     Abstract available


  233. BERGER DMS, van den Berg NS, van der Noort V, van der Hiel B, et al
    Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region.
    J Nucl Med. 2021;62:1357-1362.
    PubMed     Abstract available


  234. ZHU W, Cheng Y, Jia R, Zhao H, et al
    A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors.
    J Nucl Med. 2021;62:1398-1405.
    PubMed     Abstract available


    September 2021
  235. TAHERPOUR J, Jaber M, Voges B, Apostolova I, et al
    Predicting the outcome of epilepsy surgery by covariance pattern analysis of ictal perfusion SPECT.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262702. doi: 10.2967/jnumed.121.262702.
    PubMed     Abstract available


  236. XU M, Zhang P, Ding J, Chen J, et al
    Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262533. doi: 10.2967/jnumed.121.262533.
    PubMed     Abstract available


  237. PALESTRO C, Clark A, Grady E, Heiba S, et al
    Appropriate Use Criteria for the Use of Nuclear Medicine in Musculoskeletal Infection Imaging.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262579. doi: 10.2967/jnumed.121.262579.
    PubMed    


  238. CROMPTON J, Armstrong WR, Eckardt MA, Seyedroudbari A, et al
    (18)F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262502. doi: 10.2967/jnumed.121.262502.
    PubMed     Abstract available


  239. JADVAR H, Calais J, Fanti S, Feng F, et al
    Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.263262. doi: 10.2967/jnumed.121.263262.
    PubMed    


  240. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available


  241. HU Y, Liu G, Yu H, Wang Y, et al
    Feasibility of ultra-low (18)F-FDG activity acquisitions using total-body PET/CT.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262038. doi: 10.2967/jnumed.121.262038.
    PubMed     Abstract available


  242. ZHAO L, Niu B, Fang J, Pang Y, et al
    Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer.
    J Nucl Med. 2021 Sep 23. pii: jnumed.121.263016. doi: 10.2967/jnumed.121.263016.
    PubMed     Abstract available


  243. WEBER M, Schmitz J, Maric I, Pabst KM, et al
    Diagnostic performance of [(124)I]m-iodobenzylguanidine PET/CT in patients with pheochromocytoma.
    J Nucl Med. 2021 Sep 23. pii: jnumed.121.262797. doi: 10.2967/jnumed.121.262797.
    PubMed     Abstract available


  244. SONG H, Iagaru A, Rowe SP
    (18)F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262989. doi: 10.2967/jnumed.121.262989.
    PubMed     Abstract available


  245. NIENHUIS PH, Antunes IF, Glaudemans AWJM, Jalving M, et al
    (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262368. doi: 10.2967/jnumed.121.262368.
    PubMed     Abstract available


  246. ZANOVELLO M, Soraru G, Campi C, Anglani M, et al
    Brainstem glucose hypermetabolism in ALS/FTD and shorten survival: a (18)F-FDG PET/MR study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262232. doi: 10.2967/jnumed.121.262232.
    PubMed     Abstract available


  247. MHLANGA J, Haq A, Derenoncourt P, Bhandiwad A, et al
    (18)F-FDG Positron Emission Tomography in Myocardial Viability Assessment: A Practical and Time Efficient Protocol.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262432. doi: 10.2967/jnumed.121.262432.
    PubMed     Abstract available


  248. LAFFON E, Marthan R
    On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessels Vasculitis.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.263060. doi: 10.2967/jnumed.121.263060.
    PubMed    


  249. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    PubMed     Abstract available


  250. CARRASQUILLO JA, Chen CC, Jha A, Pacak K, et al
    Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
    J Nucl Med. 2021;62:1192-1199.
    PubMed     Abstract available


  251. CZERNIN J, Radu C, Ribas A
    Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas.
    J Nucl Med. 2021;62:1178-1180.
    PubMed    


  252. JALLINOJA VIJ, Houghton JL
    Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.
    J Nucl Med. 2021;62:1200-1206.
    PubMed     Abstract available


    August 2021
  253. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    PubMed     Abstract available


  254. BAG AK, Wing MN, Sabin ND, Hwang SN, et al
    [(11)C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence.
    J Nucl Med. 2021 Aug 26. pii: jnumed.120.261891. doi: 10.2967/jnumed.120.261891.
    PubMed     Abstract available


  255. IQBAL R, Yaqub M, Oprea-Lager DE, Liu Y, et al
    Biodistribution of (18)F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262500. doi: 10.2967/jnumed.121.262500.
    PubMed     Abstract available


  256. LO AC, James LP, Prica A, Raymakers A, et al
    Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262324. doi: 10.2967/jnumed.121.262324.
    PubMed     Abstract available


  257. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
    PubMed     Abstract available


  258. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available


  259. PAQUETTE M, Espinosa-Bentancourt E, Lavallee E, Phoenix S, et al
    (18)F-4FMFES and (18)F-FDG PET/CT in ER+ endometrial carcinomas: preliminary report.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262617. doi: 10.2967/jnumed.121.262617.
    PubMed     Abstract available


  260. MATHEY C, Keyzer C, Blocklet D, Van Simaeys G, et al
    (18)F-fluorocholine PET/CT is more sensitive than (11)C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262395. doi: 10.2967/jnumed.121.262395.
    PubMed     Abstract available


  261. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
    PubMed     Abstract available


  262. HOFMAN MS
    Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262890. doi: 10.2967/jnumed.121.262890.
    PubMed    


  263. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    PubMed     Abstract available


  264. LU P, Benabdallah N, Jiang W, Simons BW, et al
    Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262270. doi: 10.2967/jnumed.121.262270.
    PubMed     Abstract available


  265. NAGANAWA M, Nabulsi NB, Matuskey D, Henry S, et al
    Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer (11)C-TASP699.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262430. doi: 10.2967/jnumed.121.262430.
    PubMed     Abstract available


  266. FENG T, Wu Y, Zhao Y, Xu T, et al
    Whole-body Parametric Imaging of FDG PET using uEXPLORER with Reduced Scan Time.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.261651. doi: 10.2967/jnumed.120.261651.
    PubMed     Abstract available


  267. BRAGINA O, Chernov V, Schulga A, Konovalova E, et al
    Phase I trial of (99m)Tc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262542. doi: 10.2967/jnumed.121.262542.
    PubMed     Abstract available


  268. STABIN MG, Wendt RE 3rd, Flux GD
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 1. Collection of Data for Radiopharmaceutical Dosimetry.
    J Nucl Med. 2021 Aug 5. pii: jnumed.120.259200. doi: 10.2967/jnumed.120.259200.
    PubMed     Abstract available


  269. STABIN MG, Wendt RE 3rd, Flux GD
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 2. Data Analysis and Dosimetry.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262034. doi: 10.2967/jnumed.121.262034.
    PubMed     Abstract available


  270. BRENDLE C, Maier C, Bender B, Schittenhelm J, et al
    Impact of (18)F-FET PET/MR on clinical management of brain tumor patients.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262051. doi: 10.2967/jnumed.121.262051.
    PubMed     Abstract available


  271. IAGARU A
    2021 SNMMI Highlights Lecture: General Nuclear Medicine.
    J Nucl Med. 2021;62:12N-17N.
    PubMed    



  272. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    



  273. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    


  274. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    PubMed    


  275. CARRASQUILLO JA, Chen CC, Jha A, Ling A, et al
    Imaging of Pheochromocytoma and Paraganglioma.
    J Nucl Med. 2021;62:1033-1042.
    PubMed     Abstract available


  276. HOFMAN MS, Calais J, Czernin J
    Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jeremie Calais.
    J Nucl Med. 2021;62:1027-1030.
    PubMed    


  277. WAHL RL, Dilsizian V, Palestro CJ
    At Last, (18)F-FDG for Inflammation and Infection!
    J Nucl Med. 2021;62:1048-1049.
    PubMed    


  278. CLEMENTE GS, Antunes IF, Kurhade S, van den Berg MPM, et al
    Mapping Arginase Expression with (18)F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary alpha-Amino Acids.
    J Nucl Med. 2021;62:1163-1170.
    PubMed     Abstract available


  279. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    PubMed     Abstract available


  280. LASSEN ML, Otaki Y, Kavanagh P, Miller RJH, et al
    Simulation of Low-Dose Protocols for Myocardial Perfusion (82)Rb Imaging.
    J Nucl Med. 2021;62:1112-1117.
    PubMed     Abstract available


  281. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    PubMed     Abstract available


    July 2021
  282. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    PubMed     Abstract available


  283. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    PubMed     Abstract available


  284. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    PubMed     Abstract available


  285. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available


  286. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
    (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
    PubMed     Abstract available


  287. WOFF E, Salvatore L, Marmorino F, Genovesi D, et al
    Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
    J Nucl Med. 2021 Jul 29. pii: jnumed.120.245357. doi: 10.2967/jnumed.120.245357.
    PubMed     Abstract available


  288. CATANA C, Laforest R, An H, Boada F, et al
    A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.261881. doi: 10.2967/jnumed.120.261881.
    PubMed     Abstract available


  289. PRENOSIL GA, Sari H, Furstner M, Afshar-Oromieh A, et al
    Performance Characteristics of the Biograph Vision Quadra PET/CT system with long axial field of view using the NEMA NU 2-2018 Standard.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.261972. doi: 10.2967/jnumed.121.261972.
    PubMed     Abstract available


  290. OREVI M, Chicheportiche A, Ben-Haim S
    Lessons learned from post-COVID-19 vaccination PET/CT studies.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262348. doi: 10.2967/jnumed.121.262348.
    PubMed     Abstract available


  291. GANS D, Braet P, Ahmadi Bidakhvidi N, Deroose CM, et al
    (18)F-FDG PET-CT sheds a Light on a Case of Hyponatremia.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262369. doi: 10.2967/jnumed.121.262369.
    PubMed     Abstract available


  292. VONKEN EPA, Bruijnen RCG, Snijders TJ, Seute T, et al
    Intra-arterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262491. doi: 10.2967/jnumed.121.262491.
    PubMed     Abstract available


  293. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available


  294. SANCHEZ-CATASUS C, Bohnen NI, D'Cruz N, Muller M, et al
    Striatal acetylcholine-dopamine imbalance in Parkinson's disease: in vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261939. doi: 10.2967/jnumed.121.261939.
    PubMed     Abstract available


  295. IMPERIALE A, Boursier C, Sahakian N, Ouvrard E, et al
    Values of (68)Ga-DOTATOC and Carbidopa-assisted (18)F-DOPA PET/CT for insulinoma localization.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.262401. doi: 10.2967/jnumed.121.262401.
    PubMed     Abstract available


  296. THORNTON A, Fraioli F, Wan S, Garthwaite HS, et al
    Evolution of (18)F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.262296. doi: 10.2967/jnumed.121.262296.
    PubMed     Abstract available


  297. BENZ MR, Armstrong WR, Ceci F, Polverari G, et al
    (18)F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261952. doi: 10.2967/jnumed.121.261952.
    PubMed     Abstract available


  298. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available


  299. READER AJ, Schramm G
    AI for PET image reconstruction.
    J Nucl Med. 2021 Jul 8. pii: jnumed.121.262303. doi: 10.2967/jnumed.121.262303.
    PubMed    


  300. IM C, Kim H, Zaheer J, Kim JY, et al
    PET tracing of biodistribution for orally administered (64)Cu-labeled polystyrene in mice.
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.256982. doi: 10.2967/jnumed.120.256982.
    PubMed     Abstract available


  301. BOSS M, Rottenburger C, Brenner W, Blankenstein O, et al
    (68)Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism.
    J Nucl Med. 2021 Jul 2. pii: jnumed.121.262327. doi: 10.2967/jnumed.121.262327.
    PubMed     Abstract available


  302. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
    Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
    PubMed     Abstract available


  303. STATES LJ, Davis JC, Hamel SM, Becker SA, et al
    (18)F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  304. WAHL R
    Nuclear Medicine Innovations: Providing Access for All.
    J Nucl Med. 2021;62:16N.
    PubMed    


  305. MARZELLA L, Czernin J, Hope T
    Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.
    J Nucl Med. 2021;62:881-883.
    PubMed    


  306. BLAZHENETS G, Schroeter N, Bormann T, Thurow J, et al
    Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients.
    J Nucl Med. 2021;62:910-915.
    PubMed     Abstract available


  307. WILD D, Antwi K, Fani M, Christ ER, et al
    Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  308. HINDIE E, Schwartz P, Avram AM, Imperiale A, et al
    Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  309. CRANDALL JP, Wahl RL
    Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  310. SUNDIN A, Hindie E, Avram AM, Tabarin A, et al
    A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


    June 2021
  311. BARCA C, Kiliaan AJ, Foray C, Wachsmuth L, et al
    A longitudinal PET/MR imaging study of colony stimulating factor-1 receptor-mediated microglia depletion in experimental stroke.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262279. doi: 10.2967/jnumed.121.262279.
    PubMed     Abstract available


  312. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262710. doi: 10.2967/jnumed.121.262710.
    PubMed    


  313. MEIER SR, Sehlin D, Roshanbin S, Lim Falk V, et al
    (11)C-PIB and (124)I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262083. doi: 10.2967/jnumed.121.262083.
    PubMed     Abstract available


  314. WAKFIE-CORIEH CG, Ferrando-Castagnetto F, Blanes Garcia AM, Garcia-Esquinas MG, et al
    Incidental findings suggestive of COVID-19 pneumonia in oncological patients undergoing 18F-FDG PET/CT studies: association between metabolic and structural lung changes.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.261915. doi: 10.2967/jnumed.121.261915.
    PubMed     Abstract available


  315. ZHANG X, Landgraf L, Bailis N, Unger M, et al
    Image-guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?
    J Nucl Med. 2021 Jun 4. pii: jnumed.120.256230. doi: 10.2967/jnumed.120.256230.
    PubMed     Abstract available


  316. DASHORA HR, Rosenblum JS, Quinn KA, Alessi H, et al
    Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262326. doi: 10.2967/jnumed.121.262326.
    PubMed     Abstract available


  317. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    PubMed     Abstract available


  318. ORELLANA P, Mut F, Estrada E, Lette MM, et al
    Status of Nuclear Medicine in Latin America and the Caribbean: IAEA Analysis of Development in the Past 6 Years.
    J Nucl Med. 2021;62:23N-29N.
    PubMed    


  319. ALLIS J, Mankoff D
    Industry Perspective on the Changing Nuclear Medicine Landscape: A Conversation Between Jonathan Allis and David Mankoff.
    J Nucl Med. 2021;62:749-751.
    PubMed    


  320. GAN HK, Burge M, Solomon B, Lee ST, et al
    A Phase 1 and Biodistribution Study of ABT-806i, an (111)In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
    J Nucl Med. 2021;62:787-794.
    PubMed     Abstract available


  321. EBBERS SC, Barentsz MW, de Keizer B, Krijger GC, et al
    A Rapid and Safe Infusion Protocol for (177)Lu Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2021;62:816-822.
    PubMed     Abstract available


  322. ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
    Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.
    J Nucl Med. 2021;62:833-838.
    PubMed     Abstract available


    May 2021
  323. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    PubMed     Abstract available


  324. RAMAN F, Fang YD, Grandhi S, Murchison CF, et al
    Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures.
    J Nucl Med. 2021 May 28. pii: jnumed.120.254490. doi: 10.2967/jnumed.120.254490.
    PubMed     Abstract available


  325. JIN X, Wei M, Wang S, Wang G, et al
    Detecting fibroblast activation proteins in lymphoma using (68)Ga-FAPI PET/CT.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262134. doi: 10.2967/jnumed.121.262134.
    PubMed     Abstract available


  326. JACENE HA, Liu M, Cheng SC, Abbott A, et al
    Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5alpha-dihydrotestosterone-PET: A Pilot Study.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262068. doi: 10.2967/jnumed.121.262068.
    PubMed     Abstract available


  327. SEBAN RD, Champion L, Muneer I, Synn S, et al
    Potential theranostic role of bone marrow glucose metabolism on baseline [18F]-FDG PET/CT in metastatic melanoma.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262361. doi: 10.2967/jnumed.121.262361.
    PubMed    


  328. KRAUS S, Dierks A, Rasche L, Kertels O, et al
    (68)Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262206. doi: 10.2967/jnumed.121.262206.
    PubMed     Abstract available


  329. MUNOZ C, Ellis S, Nekolla SG, Kunze KP, et al
    MR-guided motion-corrected PET image reconstruction for cardiac PET-MR.
    J Nucl Med. 2021 May 28. pii: jnumed.120.254235. doi: 10.2967/jnumed.120.254235.
    PubMed     Abstract available


  330. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    PubMed     Abstract available


  331. BIECHELE G, Sebastian Monasor L, Wind K, Blume T, et al
    Glitter in the Darkness? Non-fibrillar beta-amyloid Plaque Components Significantly Impact the beta-amyloid PET Signal in Mouse Models of Alzheimer's Disease.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261858. doi: 10.2967/jnumed.120.261858.
    PubMed     Abstract available


  332. ZARAGORI T, Oster J, Roch V, Hossu G, et al
    (18)F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261545. doi: 10.2967/jnumed.120.261545.
    PubMed     Abstract available


  333. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available


  334. MORAWITZ J, Bruckmann NM, Dietzel F, Ullrich T, et al
    Determining the axillary nodal status with four current imaging modalities including (18)F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.
    J Nucl Med. 2021 May 20. pii: jnumed.121.262009. doi: 10.2967/jnumed.121.262009.
    PubMed     Abstract available


  335. COLLET S, Guillamo JS, Berro DH, Chakhoyan A, et al
    Simultaneous mapping of vasculature, hypoxia and proliferation using DSC-MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma.
    J Nucl Med. 2021 May 20. pii: jnumed.120.249524. doi: 10.2967/jnumed.120.249524.
    PubMed     Abstract available


  336. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    PubMed     Abstract available


  337. EL-ATOUM B, Ebert M, Bucher B, Afify Z, et al
    Is (18)F-FDG PET/CT effective in identifying true residual disease after treatment of pediatric PTLD?
    J Nucl Med. 2021 May 14. pii: jnumed.121.262414. doi: 10.2967/jnumed.121.262414.
    PubMed    


  338. BOERS J, Loudini N, Brunsch CL, Koza SA, et al
    Value of (18)F-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study.
    J Nucl Med. 2021 May 14. pii: jnumed.120.256826. doi: 10.2967/jnumed.120.256826.
    PubMed     Abstract available


  339. HENDERSON TA, DeBruin S, Briandet P
    (18)F-FDG PET National Coverage Determination for Infection/Inflammation Retired.
    J Nucl Med. 2021;62:18N-22N.
    PubMed    


  340. WAHL RL, Ahuja S, Clarke B
    Current Landscape of Radiopharmaceutical Therapies: SNMMI Therapy Task Force Survey.
    J Nucl Med. 2021;62:11N-16N.
    PubMed    



  341. Challenges and Promise for Nuclear Medicine in Africa: A Conversation Between Mike Sathekge and Johannes Czernin.
    J Nucl Med. 2021;62:593-595.
    PubMed    


  342. YOSHINAGA K, Abe T, Okamoto S, Uchiyama Y, et al
    Effects of Repeated (131)I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors.
    J Nucl Med. 2021;62:685-694.
    PubMed     Abstract available


  343. NAZERI A, Crandall JP, Fraum TJ, Wahl RL, et al
    Repeatability of Radiomic Features of Brown Adipose Tissue.
    J Nucl Med. 2021;62:700-706.
    PubMed     Abstract available


  344. FENG T, Zhao Y, Shi H, Li H, et al
    Total-Body Quantitative Parametric Imaging of Early Kinetics of (18)F-FDG.
    J Nucl Med. 2021;62:738-744.
    PubMed     Abstract available


  345. SCHAEFER WM, Knollmann D, Meyer PT
    Q/V-SPECT CT in times of COVID-19: Changing the order to improve safety without sacrificing accuracy.
    J Nucl Med. 2021 May 7. pii: jnumed.120.261263. doi: 10.2967/jnumed.120.261263.
    PubMed    


    April 2021
  346. KESSLER L, Ferdinandus J, Hirmas N, Bauer S, et al
    Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262096. doi: 10.2967/jnumed.121.262096.
    PubMed     Abstract available


  347. COHEN AS, Grudzinski J, Smith GT, Peterson TE, et al
    First-in-human PET imaging and estimated radiation dosimetry of L-[5-(11)C]-glutamine in patients with metastatic colorectal cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.261594. doi: 10.2967/jnumed.120.261594.
    PubMed     Abstract available


  348. CHENG JL, Dibble EH, Baird GL, Gordon LL, et al
    Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.260711. doi: 10.2967/jnumed.120.260711.
    PubMed     Abstract available


  349. KWIECINSKI J, Tzolos E, Meah M, Cadet S, et al
    Machine-learning with (18)F-sodium fluoride PET and quantitative plaque analysis on CT angiography for the future risk of myocardial infarction.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262283. doi: 10.2967/jnumed.121.262283.
    PubMed     Abstract available


  350. FENDLER WP, Herrmann K, Eiber M
    Nuclear Medicine beyond VISION.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262441. doi: 10.2967/jnumed.121.262441.
    PubMed    


  351. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed     Abstract available


  352. EIFER M, Tau N, Alhoubani Y, Kanana N, et al
    Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262194. doi: 10.2967/jnumed.121.262194.
    PubMed     Abstract available


  353. GHZALLY Y, Imanli H, Smith M, Mahat J, et al
    Metabolic Scar Assessment with (18)F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.246413. doi: 10.2967/jnumed.120.246413.
    PubMed     Abstract available


  354. GOGOLA A, Minhas DS, Villemagne VL, Cohen AD, et al
    Direct comparison of the tau PET tracers [(18)F]flortaucipir and [(18)F]MK-6240 in human subjects.
    J Nucl Med. 2021 Apr 16. pii: jnumed.120.254961. doi: 10.2967/jnumed.120.254961.
    PubMed     Abstract available


  355. YOUNG AJ, Pantel AR, Viswanath V, Dominguez TL, et al
    Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted (18)F-FluorThanatrace ((18)F-FTT) PET images of ovarian cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.261894. doi: 10.2967/jnumed.121.261894.
    PubMed     Abstract available


  356. QIN C, Shao F, Gai Y, Liu Q, et al
    (68)Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2021 Apr 16. pii: jnumed.120.258467. doi: 10.2967/jnumed.120.258467.
    PubMed     Abstract available


  357. LUKEY PT, Wilson FJ
    Quantification of the alphavbeta6 Integrin by PET/CT Imaging in the Lungs of Patients after SARS-CoV2 Infection and Comparison to Fibrotic Lungs.
    J Nucl Med. 2021 Apr 9. pii: jnumed.121.262342. doi: 10.2967/jnumed.121.262342.
    PubMed    


  358. GUGLIELMETTI C, Levi J, Huynh TL, Tiret B, et al
    Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using (18)F-FAraG PET and MRI.
    J Nucl Med. 2021 Apr 9. pii: jnumed.120.259325. doi: 10.2967/jnumed.120.259325.
    PubMed     Abstract available


  359. KUO HT, Lin KS, Zhang Z, Uribe CF, et al
    (177)Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    J Nucl Med. 2021;62:521-527.
    PubMed     Abstract available


    March 2021
  360. ALSULTAN AA, van Roekel C, Barentsz MW, Smits MLJ, et al
    Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.255745. doi: 10.2967/jnumed.120.255745.
    PubMed     Abstract available


  361. WU H, Czernin J
    A Conversation Between Hong Wu and Johannes Czernin.
    J Nucl Med. 2021;62:293-295.
    PubMed    


  362. LODGE MA
    Phantom Preparation Using a Dilution Technique.
    J Nucl Med. 2021;62:303.
    PubMed    


  363. ALBRECHT J, Exner S, Grotzinger C, Prasad S, et al
    Multimodal Imaging of 2-Cycle PRRT with (177)Lu-DOTA-JR11 and (177)Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.
    J Nucl Med. 2021;62:393-398.
    PubMed     Abstract available


  364. BARRINGTON SF, Zwezerijnen BGJC, de Vet HCW, Heymans MW, et al
    Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
    J Nucl Med. 2021;62:332-337.
    PubMed     Abstract available


  365. PEREIRA PMR, Norfleet J, Lewis JS, Escorcia FE, et al
    Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition.
    J Nucl Med. 2021;62:366-371.
    PubMed     Abstract available


    February 2021
  366. SUH M, Im HJ, Ryoo HG, Kang KW, et al
    Head to head comparison of (68)Ga-NGUL and (68)Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study.
    J Nucl Med. 2021 Feb 26. pii: jnumed.120.258434. doi: 10.2967/jnumed.120.258434.
    PubMed     Abstract available


  367. SARTOR O, Hope TA, Calais J, Fendler WP, et al
    Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.
    J Nucl Med. 2021;62:146-148.
    PubMed    


  368. CARLUCCI G, Ippisch R, Slavik R, Mishoe A, et al
    (68)Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.
    J Nucl Med. 2021;62:149-155.
    PubMed     Abstract available


  369. ZANOTTI-FREGONARA P, Lammertsma AA, Innis RB
    (11)C Dosimetry Scans Should Be Abandoned.
    J Nucl Med. 2021;62:158-159.
    PubMed    


  370. ALTMANN A, Haberkorn U, Siveke J
    The Latest Developments in Imaging of Fibroblast Activation Protein.
    J Nucl Med. 2021;62:160-167.
    PubMed     Abstract available


  371. SLOMKA PJ, Moody JB, Miller RJH, Renaud JM, et al
    Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications.
    J Nucl Med. 2021;62:168-176.
    PubMed     Abstract available


  372. AHMED H, Wallimann R, Haider A, Hosseini V, et al
    Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
    J Nucl Med. 2021;62:259-265.
    PubMed     Abstract available


  373. HADDAD J, Latoche JD, Nigam S, Bellavia MC, et al
    Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
    J Nucl Med. 2021;62:280-286.
    PubMed     Abstract available


    January 2021
  374. ARMSTRONG WR, Gafita A, Zhu S, Thin P, et al
    The impact of monosodium glutamate on (68)Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled, imaging study.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.257931. doi: 10.2967/jnumed.120.257931.
    PubMed     Abstract available


  375. BODAR YJL, Koene BPF, Jansen BHE, Cysouw MCF, et al
    Standardized Uptake Values are Adequate Measures of Lesional (18)F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.260232. doi: 10.2967/jnumed.120.260232.
    PubMed     Abstract available


  376. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.
    PubMed    


  377. BUVAT I, Herrmann K, Stremitzer A, Tobia K, et al
    Irene Buvat and Ken Herrmann Talk with Alexander Stremitzer, Kevin Tobia, and Aileen Nielsen.
    J Nucl Med. 2021;62:3-5.
    PubMed    


  378. PRICE WN 2ND, Gerke S, Cohen IG
    How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?
    J Nucl Med. 2021;62:15-16.
    PubMed    


  379. TOBIA K, Nielsen A, Stremitzer A
    When Does Physician Use of AI Increase Liability?
    J Nucl Med. 2021;62:17-21.
    PubMed     Abstract available


  380. CAPOBIANCO N, Meignan M, Cottereau AS, Vercellino L, et al
    Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2021;62:30-36.
    PubMed     Abstract available


  381. ZIESSMAN HA, Jeyasingam M, Khan AU, McMahan Z, et al
    Experience with Esophagogastrointestinal Transit Scintigraphy in the Initial 229 Patients: Multiple Regions of Dysmotility Are Common.
    J Nucl Med. 2021;62:115-122.
    PubMed     Abstract available


    November 2020
  382. AYATI N, Lee ST, Zakavi SR, Cheng M, et al
    Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
    PubMed     Abstract available


    October 2020
  383. VIDAL-SICART S, Rioja ME, Prieto A, Goni E, et al
    Sentinel Lymph Node Biopsy in breast cancer with (99m)Tc-Tilmanocept: A novel tracer in the real life. A multicenter study.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.252064. doi: 10.2967/jnumed.120.252064.
    PubMed     Abstract available


    August 2020
  384. MACASKILL MG, Stadulyte A, Williams L, Morgan TEF, et al
    Quantification of macrophage-driven inflammation during myocardial infarction with (18)F-LW223, a novel TSPO radiotracer with binding independent of the rs6971 human polymorphism.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.243600. doi: 10.2967/jnumed.120.243600.
    PubMed     Abstract available


  385. KUMAR M, Salem K, Jeffery JJ, Yan Y, et al
    Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.249508. doi: 10.2967/jnumed.120.249508.
    PubMed     Abstract available


  386. NICOLAY NH, Ruhle A, Wiedenmann N, Niedermann G, et al
    Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer - Results from a Prospective Imaging Trial.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248633. doi: 10.2967/jnumed.120.248633.
    PubMed     Abstract available


  387. BRAGINA O, von Witting E, Garousi J, Zelchan R, et al
    Phase I study of (99m)Tc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.248799. doi: 10.2967/jnumed.120.248799.
    PubMed     Abstract available


    June 2020
  388. VAN ROEKEL C, Bastiaannet R, Smits MLJ, Bruijnen RC, et al
    Dose-effect relationships of holmium-166 radioembolization in colorectal cancer.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.243832. doi: 10.2967/jnumed.120.243832.
    PubMed     Abstract available


    May 2020
  389. HARSINI S, Saprunoff H, Alden TM, Mohammadi B, et al
    The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
    J Nucl Med. 2020 May 8. pii: jnumed.120.246983. doi: 10.2967/jnumed.120.246983.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Nuclear Medicine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: